APRINOIA Therapeutics Announces Fast Track Designation Granted by U.S. FDA to APN-1607 (florzolotau) for the Diagnosis of Progressive Supranuclear Palsy
20 mai 2024 08h00 HE
|
APRINOIA Therapeutics, Inc.
CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics (“Aprinoia” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and precision...
APRINOIA Therapeutics Announces Strategic Investment From The Alzheimer’s Drug Discovery Foundation (ADDF)
11 sept. 2023 07h00 HE
|
APRINOIA Therapeutics, Inc.
Investment Supports APRINOIA’s Effort to Bring Precision Medicine to Neuroscience, Advancing APRINOIA’s Diagnostic and Therapeutic PipelinesFunding Supports APRINOIA’s Goal to Bring a Central Nervous...
APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer
28 août 2023 11h00 HE
|
APRINOIA Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics (“APRINOIA”), a global clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for...